Is IDEXX Laboratories Inc (IDXX) overvalued? · P/E 40, rev $2.36B
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
This page asks whether IDEXX Laboratories Inc (IDXX) looks expensive on cached numbers — not a short thesis.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IDXX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IDXX stock page for the full model, not this heading.
Not investment advice.